Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2021 / Nov / Discrepancy Distress?
Microbiology & Immunology Microbiology and Immunology Infectious Disease

Discrepancy Distress?

Not all COVID-19 tests yield the same result – and, in some cases, this can mean the difference between positive and negative

By Michael Schubert 11/24/2021 Quick Read (pre 2022) 1 min read

Share

When COVID-19 first hit, Montefiore-Einstein’s pandemic response team took on the task of implementing diagnostic COVID-19 testing. To that end, they developed and evaluated an ELISA that measured IgG and IgA antibodies to the SARS-CoV-2 spike (S) protein (1). This assay, the subject of a laboratory-developed test application, was transferred to the clinical laboratory and also used in a study of convalescent plasma as a therapeutic agent for COVID-19.

“The most common issue in SARS-CoV-2 testing and interpretation is understanding the antigen used for the test and how it relates to vaccination response,” says response team member Louis M. Weiss, who was part of a team that investigated the accuracy, reliability, and discordance in SARS-CoV-2 testing platforms (2). He explains, “It is critical to understand the parameters of testing and what a test means in a clinical setting to provide useful information to our clinical colleagues. Given the urgency to develop these tests and lack of standardized material during the early stages of the pandemic, most SARS-CoV-2 IgG antibody tests were developed and approved as qualitative assays with a positive or negative result reported based on a cutoff value.” 

In response, the Montefiore-Einstein pandemic response team investigated tests in a real-world testing scenario in which patients are only tested once – and found a lower sensitivity with the current cutoff compared with published sensitivities on several of these commercial tests (3). “The assays evaluated performed well based on the sensitivity and specificity studies,” explains Weiss. “Their main shortcoming was their qualitative reporting. Discrepancy analysis demonstrated that patients who had grey zone results (i.e., just below the cutoff) on some assays had positive results on others. It should be appreciated, however, that all of the assays tested in this study performed well in identifying patients with past COVID-19 infection, which is the major role for these tests in the clinical setting.”

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. RH Bortz 3rd et al., mSphere, 6, e00224 (2021). PMID: 33883259.
  2. SN Wontakal et al., Open Forum Infect Dis, 8, ofab144 (2021). PMID: 34316498.
  3. SK Forest et al., Arch Pathol Lab Med, 145, 929 (2021). PMID: 33821952.

About the Author(s)

Michael Schubert

While obtaining degrees in biology from the University of Alberta and biochemistry from Penn State College of Medicine, I worked as a freelance science and medical writer. I was able to hone my skills in research, presentation and scientific writing by assembling grants and journal articles, speaking at international conferences, and consulting on topics ranging from medical education to comic book science. As much as I’ve enjoyed designing new bacteria and plausible superheroes, though, I’m more pleased than ever to be at Texere, using my writing and editing skills to create great content for a professional audience.

More Articles by Michael Schubert

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

The Viral Frontier
Infectious Disease
The Viral Frontier

January 23, 2024

1 min read

The latest on the UK COVID-19 inquiry

What’s New in Infectious Disease? (December 2021)
Infectious Disease
What’s New in Infectious Disease?

December 23, 2021

1 min read

The latest research and news on COVID-19 and the infectious disease landscape

Immunology Insights
Infectious Disease
Immunology Insights

January 13, 2022

1 min read

The latest research in pathology and laboratory medicine

Pneumocystis Mysteries
Infectious Disease
Pneumocystis Mysteries

January 21, 2022

1 min read

What is the correct name for this pneumonia-causing pathogen?

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.